Use of DARPP-32 to increase interactions between EGFR and ERBB3 and to promote gastric cancer resistance to gefitinib.
Shoumin Zhu
No relevant relationships to disclose
Abbes Belkhiri
No relevant relationships to disclose
Alexander Zaika
No relevant relationships to disclose
Wael El-Rifai
No relevant relationships to disclose